Advertisement

Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence

Published:January 07, 2022DOI:https://doi.org/10.1016/j.clcc.2022.01.002

      Abstract

      Background

      Short course radiation-based total neoadjuvant therapy can improve disease-free survival for patients with high-risk locally advanced rectal cancer. Tumors that involve or threaten the circumferential resection margin have a particularly high risk of local recurrence. Intraoperative radiation therapy enables treatment escalation at the threatened or involved margin at the time of surgery.

      Patients and Methods

      Patients with rectal adenocarcinoma treated with preoperative short course radiotherapy-based total neoadjuvant therapy and intraoperative radiation at the time of surgery were identified. All patients had a threatened or involved circumferential resection margin on magnetic resonance imaging at the time of diagnosis. Treatment details, radiation toxicities, postoperative complications and oncologic outcomes were recorded.

      Results

      Ten patients received intraoperative radiation after short course radiation-based total neoadjuvant therapy. All patients had an involved or threatened circumferential resection margin, 60% had extramural venous invasion, and 60% had positive lateral pelvic lymph nodes. Seven patients had negative surgical margins (≥ 2 mm), and 3 patients had an R1 resection with radial margins < 2 mm. The median [IQR] length of hospitalization after surgery was 11 [7-14] days. Three patients required readmission and 2 patients required reoperation due to complications including anastamotic leak and abscess. With a median follow up of 19.5 months postoperatively, no patient developed a pelvic recurrence, and 6 patients developed distant recurrences.

      Conclusions

      The use of intraoperative radiation after a short course radiotherapy-based neoadjuvant therapy is safe and feasible. Further data are needed to determine whether the addition of intraoperative radiation improves local recurrence rates over preoperative radiation alone.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van Gijn W
        • Marijnen CA
        • Nagtegaal ID
        • et al.
        Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.
        Lancet Oncol. 2011; 12: 575-582https://doi.org/10.1016/S1470-2045(11)70097-3
        • Fleming FJ
        • Påhlman L
        • Monson JRT.
        Neoadjuvant therapy in rectal cancer.
        Dis Colon Rectum. 2011; 54: 901-912https://doi.org/10.1007/DCR.0b013e31820eeb37
        • Taylor FGM
        • Quirke P
        • Heald RJ
        • et al.
        Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.
        Ann Surg. 2011; 253: 711-719https://doi.org/10.1097/SLA.0b013e31820b8d52
        • Deng X
        • Liu P
        • Jiang D
        • et al.
        Neoadjuvant radiotherapy versus surgery alone for stage II/III mid-low rectal cancer with or without high-risk factors: a prospective multicenter stratified randomized trial.
        Ann Surg. 2020; 272: 1060-1069https://doi.org/10.1097/SLA.0000000000003649
        • Yamamoto T
        • Kawada K
        • Hida K
        • et al.
        Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns.
        Int J Clin Oncol. 2019; 24: 677-685https://doi.org/10.1007/s10147-019-01400-6
        • Bahadoer RR
        • Dijkstra EA
        • van Etten B
        • et al.
        Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 29-42https://doi.org/10.1016/S1470-2045(20)30555-6
        • Conroy T
        • Bosset J-F
        • Etienne P-L
        • et al.
        Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 702-715https://doi.org/10.1016/S1470-2045(21)00079-6
      1. National Comprehensive Cancer Network. NCCN: rectal cancer guidelines version 1.2021. Published January 2021. Accessed July 26, 2021. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf

        • Calvo FA
        • Meirino RM
        • Orecchia R.
        Intraoperative radiation therapy part 2. Clinical results.
        Crit Rev Oncol Hematol. 2006; 59: 116-127https://doi.org/10.1016/j.critrevonc.2006.04.004
        • Fahy MR
        • Kelly ME
        • Power Foley M
        • Nugent TS
        • Shields CJ
        • Winter DC
        The role of intraoperative radiotherapy in advanced rectal cancer: a meta-analysis.
        Colorectal Dis. 2021; 23: 1998-2006https://doi.org/10.1111/codi.15698
        • Gao S
        • Delclos ME
        • Tomas LC
        • Crane CH
        • Beddar S.
        High-dose-rate remote afterloaders for intraoperative radiation therapy.
        AORN J. 2007; 86 (quiz 837-840): 827-836https://doi.org/10.1016/j.aorn.2007.07.002
        • Glynne-Jones R
        • Wyrwicz L
        • Tiret E
        • et al.
        Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2018; (Published online)https://doi.org/10.1093/annonc/mdy161
        • Glynne-Jones R
        Interpreting the RAPIDO trial: factors to consider.
        Lancet Oncol. 2021; 22: e85https://doi.org/10.1016/S1470-2045(21)00013-9
        • Giunta EF
        • Bregni G
        • Pretta A
        • et al.
        Total neoadjuvant therapy for rectal cancer: making sense of the results from the RAPIDO and PRODIGE 23 trials.
        Cancer Treat Rev. 2021; 96102177https://doi.org/10.1016/j.ctrv.2021.102177
        • Hyngstrom JR
        • Tzeng C-WD
        • Beddar S
        • et al.
        Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience: IORT for Colorectal Cancer.
        J Surg Oncol. 2014; 109: 652-658https://doi.org/10.1002/jso.23570
        • Mirnezami R
        • Chang GJ
        • Das P
        • et al.
        Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications.
        Surg Oncol. 2013; 22: 22-35https://doi.org/10.1016/j.suronc.2012.11.001
        • Birbeck KF
        • Macklin CP
        • Tiffin NJ
        • et al.
        Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery.
        Ann Surg. 2002; 235: 449-457https://doi.org/10.1097/00000658-200204000-00001
        • Dijkstra EA
        • Mul VEM
        • Hemmer PHJ
        • et al.
        Clinical selection strategies for and evaluation of intra-operative brachytherapy in patients with locally advanced rectal cancer.
        Radiother Oncol. 2021; 159: 91-97https://doi.org/10.1016/j.radonc.2021.03.010
        • Voogt ELK
        • van Rees JM
        • Hagemans JAW
        • et al.
        Intraoperative electron beam radiation therapy (IOERT) versus high-dose-rate intraoperative brachytherapy (HDR-IORT) in patients with an R1 resection for locally advanced or locally recurrent rectal cancer.
        Int J Radiat Oncol Biol Phys. 2021; 110: 1032-1043https://doi.org/10.1016/j.ijrobp.2021.02.006